Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients — MACS1295  

First or Second Line HER2-negative Breast Cancer Clinical Trial

Official title: A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid and Circulating Tumor Cell Measurements in Patients With HER2-negative Metastatic Breast Cancer Without Bone Metastasis

Status Completed

Clinical Trial Summary

This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bone Marrow Diseases
• Bone Neoplasms
• Breast Neoplasms
• First or Second Line HER2-negative Breast Cancer
• Metastatic Disease Without Bone Metastasis
• Neoplasm Metastasis
• Neoplastic Cells, Circulating

• NCT number: NCT01129336
• Study type: Interventional
• Source: Novartis
• Status: Completed
• Phase: Phase 4
• Start date: June 2010
• Completion date: August 2012